Soleno Therapeutics Class Action Lawsuit Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SLNO?
Source: Globenewswire
- Class Action Initiation: Soleno Therapeutics faces a class action lawsuit for failing to disclose safety concerns regarding its DCCR drug between March 26 and November 4, 2025, with investors able to apply as lead plaintiffs by May 5, 2026, potentially impacting the company's reputation and stock price.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno concealed significant safety issues related to DCCR during clinical trials, including fluid retention in participants, which has led to diminished investor confidence in the company's future prospects.
- Stock Price Volatility: Following a critical report from Scorpion Capital on August 15, 2025, Soleno's stock price dropped nearly 12% over two days, and after a patient death was reported on September 10, the stock fell approximately 19%, indicating a significant loss of market trust in the company's products.
- Financial Results Impact: Soleno's financial results released on November 4, 2025, revealed that the launch trajectory of DCCR was disrupted by the negative report, with a decrease in patient start forms and increased discontinuations, leading to a further 27% decline in stock price over two days, reflecting escalating market concerns about its product viability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.620
Low
75.00
Averages
110.50
High
125.00
Current: 33.620
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Class Action Lawsuit Notice
- Class Action Initiation: Soleno Therapeutics faces a class action lawsuit for failing to disclose safety concerns regarding its DCCR drug between March 26 and November 4, 2025, with investors able to apply as lead plaintiffs by May 5, 2026, potentially impacting the company's reputation and stock price.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno concealed significant safety issues related to DCCR during clinical trials, including fluid retention in participants, which has led to diminished investor confidence in the company's future prospects.
- Stock Price Volatility: Following a critical report from Scorpion Capital on August 15, 2025, Soleno's stock price dropped nearly 12% over two days, and after a patient death was reported on September 10, the stock fell approximately 19%, indicating a significant loss of market trust in the company's products.
- Financial Results Impact: Soleno's financial results released on November 4, 2025, revealed that the launch trajectory of DCCR was disrupted by the negative report, with a decrease in patient start forms and increased discontinuations, leading to a further 27% decline in stock price over two days, reflecting escalating market concerns about its product viability.
See More
Faruqi & Faruqi Investigates Soleno Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating Soleno Therapeutics for potential securities law violations between March and November 2025, which may have led to investor losses, urging investors to contact them before the May 5, 2026 deadline to seek lead plaintiff status.
- Safety Concerns Disclosure: The complaint alleges that Soleno concealed significant safety evidence related to the DCCR Phase 3 clinical trial, including issues of fluid retention in participants, raising doubts about the drug's commercial viability and potentially impacting future market performance.
- Stock Price Volatility: Following a critical report from Scorpion Capital on August 15, 2025, Soleno's stock plummeted from $77 to $68, a nearly 12% drop in just two days; additionally, on September 10, the stock fell from $70 to $57 after a patient death was reported, marking a 19% decline.
- Financial Results Impact: On November 4, 2025, Soleno reported third-quarter results indicating that the launch of DCCR was disrupted, leading to fewer patient start forms and increased discontinuations, causing the stock to drop from nearly $64 to $47 in one day, a decline of approximately 27%.
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Lawsuit Background: Soleno Therapeutics is facing a class action lawsuit from investors regarding its DCCR drug, which allegedly misrepresented safety and efficacy, covering stock purchases from March 26 to November 4, 2025, indicating significant corporate missteps in drug commercialization.
- Stock Price Plunge: Following the release of disappointing news on November 5, 2025, Soleno's shares plummeted by 26% in one day, reflecting a nearly 40% decline since August 2025, highlighting severe market concerns over the product's prospects.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety risks associated with DCCR, including issues related to fluid retention in clinical trials, leading to investor skepticism about the drug's commercial viability and damaging the company's market credibility.
- Market Reaction: In the short term, Soleno's market performance has been severely impacted, with management acknowledging disruptions in launch metrics due to a short seller's report, resulting in decreased start forms and increased discontinuations for non-serious adverse events, exacerbating investor panic.
See More
Soleno Therapeutics Faces Securities Class Action Over Clinical Trial Integrity
- Lawsuit Background: Soleno Therapeutics is facing a securities class action due to alleged integrity issues in clinical trials for its sole commercial product, DCCR (marketed as VYKAT XR), involving investor losses from March 26 to November 4, 2025, with a deadline for lead plaintiff status applications set for May 5, 2026.
- Clinical Trial Issues: The lawsuit claims that Soleno's Phase 3 clinical trials suffered from systematic problems, particularly the pivotal randomized withdrawal study C602, where unreliable data could jeopardize DCCR's FDA approval and commercial viability, directly impacting the company's revenue potential.
- Safety Concerns: The complaint highlights that DCCR's mechanism leads to fluid retention, with some patients in the 13-week trial experiencing symptoms related to pulmonary edema and potential heart failure, while management allegedly misled investors by asserting the drug had a “well-established safety profile.”
- Investor Confidence Erosion: The questions raised about the integrity of clinical data may have led investors to receive inaccurate information, resulting in diminished confidence in Soleno, which could adversely affect its stock price and market performance, reflecting potential risks in the company's transparency and compliance.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti has initiated a class action lawsuit against Soleno Therapeutics, alleging that the company failed to disclose critical information between March 26 and November 4, 2025, resulting in investor losses and highlighting serious deficiencies in corporate transparency and compliance.
- Allegation Details: The complaint asserts that Soleno and its executives systematically minimized and failed to disclose significant safety concerns related to the DCCR clinical trial, particularly excessive fluid retention among participants, which poses greater safety risks than previously disclosed, thereby affecting the product's commercial viability.
- Potential Impact: The undisclosed risks associated with DCCR may lead to higher patient discontinuation rates, reluctance from prescribers, and adverse regulatory actions post-launch, exacerbating the company's reputational and legal risks and potentially diminishing investor confidence.
- Investor Action: Affected investors must request to be appointed as lead plaintiff by May 5, 2026, indicating the importance of investor engagement in legal proceedings and their focus on corporate governance issues.
See More
Soleno Therapeutics Class Action Lawsuit Notice
- Class Action Initiation: Soleno Therapeutics faces a class action lawsuit for failing to disclose safety concerns regarding its DCCR drug between March 26 and November 4, 2025, with investors able to apply as lead plaintiffs by May 5, 2026, potentially impacting the company's reputation and stock price.
- Safety Concerns Uncovered: The lawsuit alleges that Soleno concealed significant safety issues related to DCCR during clinical trials, including fluid retention in participants, which has led to diminished investor confidence in the company's future prospects.
- Stock Price Volatility: Following a critical report from Scorpion Capital on August 15, 2025, Soleno's stock price dropped nearly 12% over two days, and after a patient death was reported on September 10, the stock fell approximately 19%, indicating a significant loss of market trust in the company's products.
- Financial Results Impact: Soleno's financial results released on November 4, 2025, revealed that the launch trajectory of DCCR was disrupted by the negative report, with a decrease in patient start forms and increased discontinuations, leading to a further 27% decline in stock price over two days, reflecting escalating market concerns about its product viability.
See More
Faruqi & Faruqi Investigates Soleno Securities Litigation
- Legal Investigation: Faruq & Faruqi LLP is investigating Soleno Therapeutics for potential securities law violations between March and November 2025, which may have led to investor losses, urging investors to contact them before the May 5, 2026 deadline to seek lead plaintiff status.
- Safety Concerns Disclosure: The complaint alleges that Soleno concealed significant safety evidence related to the DCCR Phase 3 clinical trial, including issues of fluid retention in participants, raising doubts about the drug's commercial viability and potentially impacting future market performance.
- Stock Price Volatility: Following a critical report from Scorpion Capital on August 15, 2025, Soleno's stock plummeted from $77 to $68, a nearly 12% drop in just two days; additionally, on September 10, the stock fell from $70 to $57 after a patient death was reported, marking a 19% decline.
- Financial Results Impact: On November 4, 2025, Soleno reported third-quarter results indicating that the launch of DCCR was disrupted, leading to fewer patient start forms and increased discontinuations, causing the stock to drop from nearly $64 to $47 in one day, a decline of approximately 27%.
See More
Soleno Therapeutics Faces Class Action Lawsuit
- Lawsuit Background: Soleno Therapeutics is facing a class action lawsuit from investors regarding its DCCR drug, which allegedly misrepresented safety and efficacy, covering stock purchases from March 26 to November 4, 2025, indicating significant corporate missteps in drug commercialization.
- Stock Price Plunge: Following the release of disappointing news on November 5, 2025, Soleno's shares plummeted by 26% in one day, reflecting a nearly 40% decline since August 2025, highlighting severe market concerns over the product's prospects.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety risks associated with DCCR, including issues related to fluid retention in clinical trials, leading to investor skepticism about the drug's commercial viability and damaging the company's market credibility.
- Market Reaction: In the short term, Soleno's market performance has been severely impacted, with management acknowledging disruptions in launch metrics due to a short seller's report, resulting in decreased start forms and increased discontinuations for non-serious adverse events, exacerbating investor panic.
See More
Soleno Therapeutics Faces Securities Class Action Over Clinical Trial Integrity
- Lawsuit Background: Soleno Therapeutics is facing a securities class action due to alleged integrity issues in clinical trials for its sole commercial product, DCCR (marketed as VYKAT XR), involving investor losses from March 26 to November 4, 2025, with a deadline for lead plaintiff status applications set for May 5, 2026.
- Clinical Trial Issues: The lawsuit claims that Soleno's Phase 3 clinical trials suffered from systematic problems, particularly the pivotal randomized withdrawal study C602, where unreliable data could jeopardize DCCR's FDA approval and commercial viability, directly impacting the company's revenue potential.
- Safety Concerns: The complaint highlights that DCCR's mechanism leads to fluid retention, with some patients in the 13-week trial experiencing symptoms related to pulmonary edema and potential heart failure, while management allegedly misled investors by asserting the drug had a “well-established safety profile.”
- Investor Confidence Erosion: The questions raised about the integrity of clinical data may have led investors to receive inaccurate information, resulting in diminished confidence in Soleno, which could adversely affect its stock price and market performance, reflecting potential risks in the company's transparency and compliance.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti has initiated a class action lawsuit against Soleno Therapeutics, alleging that the company failed to disclose critical information between March 26 and November 4, 2025, resulting in investor losses and highlighting serious deficiencies in corporate transparency and compliance.
- Allegation Details: The complaint asserts that Soleno and its executives systematically minimized and failed to disclose significant safety concerns related to the DCCR clinical trial, particularly excessive fluid retention among participants, which poses greater safety risks than previously disclosed, thereby affecting the product's commercial viability.
- Potential Impact: The undisclosed risks associated with DCCR may lead to higher patient discontinuation rates, reluctance from prescribers, and adverse regulatory actions post-launch, exacerbating the company's reputational and legal risks and potentially diminishing investor confidence.
- Investor Action: Affected investors must request to be appointed as lead plaintiff by May 5, 2026, indicating the importance of investor engagement in legal proceedings and their focus on corporate governance issues.
See More
